Sellas Life Sciences Reports Encouraging Immune Response From GPS Combo Trial In Ovarian Cancer
- Sellas Life Sciences Group Inc (NASDAQ: SLS) has announced updated data and initial immunobiological data from its Phase 1/2 evaluating its lead asset, galinpepimut-S (GPS), in ovarian cancer.
- Conducted in collaboration with Merck & Co Inc (NYSE: MRK), the study is investigating the combination of GPS and (Keytruda) (pembrolizumab) in patients diagnosed with second- or third-line WT1(+) relapsed or refractory platinum-resistant, advanced metastatic ovarian cancer.
- In the cohort of 11 patients, a disease control rate (DCR) of 63.6%, with a median follow-up of 15.4 weeks, was observed.
- Median progression-free survival (PFS) was 11.8 weeks. The landmark PFS rate by log-rank analysis at six months (26 weeks) was 33%.
- All patients are alive, and five patients (45.5%) are continuing to receive investigational therapy.
- Enrollment is ongoing, with a target of approximately 20 total evaluable patients.
- Immune Data showed that GPS induced WT1-specific immune responses with a substantial increase in antigen-reactive T-lymphocytes averaging +242% for CD8+ and +80.5% for CD4+ T-cells from baseline to 18 weeks post-treatment.
- The safety profile of the GPS-pembrolizumab combination was similar to that seen with pembrolizumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site.
- Price Action: SLS shares are down 8.87% at $11.91 during the market session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Ovarian CancerBiotech Earnings News Health Care General
